Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
This article reviews the precautions and adverse effects associated with vesnarinone use, and the potential mechanisms responsible for these complications as well as suggested treatment strategies. Vesnarinone, a quinolinone derivative, improves the haemodynamics and quality of life in patients with congestive heart failure (CHF); however, it is associated with the adverse effects of increased sudden cardiac death and neutropenia. These adverse effects have limited the application of vesnarinone to the general population but perhaps with continued research into vesnarinone-induced neutropenia and advances in arrhythmia management, the risk/ benefit ratio of vesnarinone may become favourable. For now, the use of vesnarinone should be limited to patients with CHF who have demonstrated a poor response to other cardiac medications and devices. These patients should be closely monitored for both cardiac and non-cardiac adverse effects.
Bertolet
Barry D
BD
Cardiology Associates of North Mississippi, Tupelo, Mississippi, USA. bbertolet@nmhs.net
D000818:Animals; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000517:prevention & control; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D011719:Pyrazines; D011804:Quinolines / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use
D011719:Pyrazines; D011804:Quinolines; D015363:Quinolones; C041667:vesnarinone